Pseudoprogression as an adverse event of glioblastoma therapy
Balañá, Carmen (Institut Catala Oncologia (ICO))
Capellades, Jaume (Hospital del Mar (Barcelona, Catalunya))
Pineda, Estela (Hospital Clínic i Provincial de Barcelona)
Estival, Anna (Institut Catala Oncologia (ICO))
Puig, Josep (Hospital Universitari de Girona Doctor Josep Trueta)
Domenech, Sira (Institut Diagnòstic per la Imatge (IDI))
Verger, Eugenia (Hospital Clínic i Provincial de Barcelona)
Pujol, Teresa (Hospital Clínic i Provincial de Barcelona)
Martinez-García, Maria (Hospital del Mar (Barcelona, Catalunya))
Oleaga, Laura (Hospital Clínic i Provincial de Barcelona)
Velarde, Josep Maria (Institut Catala Oncologia (ICO))
Mesia, Carlos (Hospital Universitari de Bellvitge)
Fuentes, Rafael (Institut Catala Oncologia (ICO))
Marruecos, Jordi (Institut Catala Oncologia (ICO))
Del Barco, Sonia (Institut Catala Oncologia (ICO))
Villà, Salvador (Institut Catala Oncologia (ICO))
Carrato, Cristina (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Gallego Rubio, Oscar (Institut d'Investigació Biomèdica Sant Pau)
Gil-Gil, Miguel (Hospital Universitari de Bellvitge)
Craven-Bartle, Jordi (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya))
Alameda, Francesc (Hospital del Mar (Barcelona, Catalunya))
Universitat Autònoma de Barcelona

Date:	2017
Abstract:	We explored predictive factors of pseudoprogression (PsP) and its impact on prognosis in a retrospective series of uniformly treated glioblastoma patients. Patients were classified as having PsP, early progression (eP) or neither (nP). We examined potential associations with clinical, molecular, and basal imaging characteristics and compared overall survival (OS), progression-free survival (PFS), post-progression survival (PPS) as well as the relationship between PFS and PPS in the three groups. Of the 256 patients studied, 56 (21. 9%) were classified as PsP, 70 (27. 3%) as eP, and 130 (50. 8%) as nP. Only MGMT methylation status was associated to PsP. MGMT methylated patients had a 3. 5-fold greater possibility of having PsP than eP (OR: 3. 48; 95% CI: 1. 606-7. 564; P = 0. 002). OS was longer for PsP than eP patients (18. 9 vs. 12. 3 months; P = 0. 0001) but was similar for PsP and nP patients (P = 0. 91). OS was shorter-though not significantly so-for PsP than nP patients (OS: 19. 5 vs. 27. 9 months; P = 0. 63) in methylated patients. PPS was similar for patients having PsP, eP or nP (PPS: 7. 2 vs. 5. 4 vs. 6. 7; P = 0. 43). Neurological deterioration occurred in 64. 3% of cases at the time they were classified as PsP and in 72. 8% of cases of eP (P = 0. 14). PsP confounds the evaluation of disease and does not confer a survival advantage in glioblastoma.
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Language:	Anglès
Document:	Article ; recerca ; Versió publicada
Subject:	MGMT ; Glioblastoma ; IDH1 mutation ; Imaging ; Pseudoprogression ; Radionecrosis
Published in:	Cancer Medicine, Vol. 6 Núm. 12 (december 2017) , p. 2858-2866, ISSN 2045-7634

DOI: 10.1002/cam4.1242
PMID: 29105360

9 p, 204.1 KB

The record appears in these collections:
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Institut d'Investigació en Ciencies de la Salut Germans Trias i Pujol (IGTP)
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Institut de Recerca Sant Pau
Articles > Research articles
Articles > Published articles